Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair M. Younossi, Quentin M. Anstee, M. Marietti, et al.
Nature Reviews Gastroenterology & Hepatology (2017) Vol. 15, Iss. 1, pp. 11-20
Closed Access | Times Cited: 4445

Showing 1-25 of 4445 citing articles:

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
Theo Vos, Amanuel Alemu Abajobir, Kalkidan Hassen Abate, et al.
The Lancet (2017) Vol. 390, Iss. 10100, pp. 1211-1259
Open Access | Times Cited: 12403
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
Spencer L James, Degu Abate, Kalkidan Hassen Abate, et al.
The Lancet (2018) Vol. 392, Iss. 10159, pp. 1789-1858
Open Access | Times Cited: 11483
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
Gregory A. Roth, Degu Abate, Kalkidan Hassen Abate, et al.
The Lancet (2018) Vol. 392, Iss. 10159, pp. 1736-1788
Open Access | Times Cited: 7388
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
Mohammed Eslam, Philip N. Newsome, Shiv Kumar Sarin, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 1, pp. 202-209
Open Access | Times Cited: 3207
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
Mohammed Eslam, Arun J. Sanyal, Jacob George, et al.
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1999-2014.e1
Open Access | Times Cited: 2579
Non-alcoholic fatty liver disease
Elizabeth E. Powell, Vincent Wai‐Sun Wong, Mary E. Rinella
The Lancet (2021) Vol. 397, Iss. 10290, pp. 2212-2224
Closed Access | Times Cited: 1803
Non-alcoholic fatty liver disease – A global public health perspective
Zobair M. Younossi
Journal of Hepatology (2018) Vol. 70, Iss. 3, pp. 531-544
Open Access | Times Cited: 1789
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
Zobair M. Younossi, Pegah Golabi, Leyla de Avila, et al.
Journal of Hepatology (2019) Vol. 71, Iss. 4, pp. 793-801
Closed Access | Times Cited: 1756
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Zobair M. Younossi, Frank Tacke, Marco Arrese, et al.
Hepatology (2018) Vol. 69, Iss. 6, pp. 2672-2682
Open Access | Times Cited: 1587
Hepatocellular carcinoma
Arndt Vogel, Tim Meyer, Gonzalo Sapisochín, et al.
The Lancet (2022) Vol. 400, Iss. 10360, pp. 1345-1362
Closed Access | Times Cited: 1290
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Rohit Loomba, Scott L. Friedman, Gerald I. Shulman
Cell (2021) Vol. 184, Iss. 10, pp. 2537-2564
Open Access | Times Cited: 1240
From NASH to HCC: current concepts and future challenges
Quentin M. Anstee, Helen L. Reeves, Elena Kotsiliti, et al.
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 16, Iss. 7, pp. 411-428
Closed Access | Times Cited: 1138
Nonalcoholic Steatohepatitis
Adam Sheka, Oyedele Adeyi, Julie Thompson, et al.
JAMA (2020) Vol. 323, Iss. 12, pp. 1175-1175
Closed Access | Times Cited: 1089
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Thomas G. Cotter, Mary E. Rinella
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1851-1864
Closed Access | Times Cited: 980
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Stergios A. Pοlyzos, Јannis Kountouras, Christos S. Mantzoros
Metabolism (2018) Vol. 92, pp. 82-97
Closed Access | Times Cited: 939
Molecular mechanisms and physiological functions of mitophagy
Mashun Onishi, Koji Yamano, Miyuki Sato, et al.
The EMBO Journal (2021) Vol. 40, Iss. 3
Open Access | Times Cited: 933
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Maurizio Parola, Massimo Pinzani
Molecular Aspects of Medicine (2018) Vol. 65, pp. 37-55
Open Access | Times Cited: 891
Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis
Jie Li, Biyao Zou, Yee Hui Yeo, et al.
˜The œLancet. Gastroenterology & hepatology (2019) Vol. 4, Iss. 5, pp. 389-398
Closed Access | Times Cited: 859
Global burden of liver disease: 2023 update
Harshad Devarbhavi, Sumeet K. Asrani, Juan Pablo Arab, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 516-537
Open Access | Times Cited: 835
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Rod S Taylor, Rebecca J. Taylor, Susan Bayliss, et al.
Gastroenterology (2020) Vol. 158, Iss. 6, pp. 1611-1625.e12
Open Access | Times Cited: 798
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
Norbert Stefan, Hans‐Ulrich Häring, Kenneth Cusi
The Lancet Diabetes & Endocrinology (2018) Vol. 7, Iss. 4, pp. 313-324
Closed Access | Times Cited: 731
Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps
Amedeo Lonardo, Fabio Nascimbeni, Stefano Ballestri, et al.
Hepatology (2019) Vol. 70, Iss. 4, pp. 1457-1469
Open Access | Times Cited: 722
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
Zobair M. Younossi, Maria Stepanova, Janus P. Ong, et al.
Clinical Gastroenterology and Hepatology (2018) Vol. 17, Iss. 4, pp. 748-755.e3
Open Access | Times Cited: 711
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
Philip N. Newsome, M. Sasso, Jonathan J Deeks, et al.
˜The œLancet. Gastroenterology & hepatology (2020) Vol. 5, Iss. 4, pp. 362-373
Open Access | Times Cited: 584
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison, Mustafa R. Bashir, Cynthia D. Guy, et al.
The Lancet (2019) Vol. 394, Iss. 10213, pp. 2012-2024
Closed Access | Times Cited: 572
Page 1 - Next Page

Scroll to top